2-Hydroxyoleic acid - Lipopharma Therapeutics

Drug Profile

2-Hydroxyoleic acid - Lipopharma Therapeutics

Alternative Names: 2-hydroxy-9-cis octadecenoic - Lipopharma; 2-OHOA - Lipopharma Therapeutics; LP561A1; Minerval

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of the Balearic Islands
  • Developer Lipopharma
  • Class Anorectics; Antineoplastics; Oleic acids
  • Mechanism of Action Membrane lipid modulators; Phosphatidylcholine ceramide phosphocholine transferase stimulants; Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma; Solid tumours

Most Recent Events

  • 15 Sep 2017 2-hydroxyoleic acid (2-OHOA) is still in phase I/IIa development for Solid tumours including malignant glioma (Lipopharma website, September 2017)
  • 05 Jun 2017 Adverse events data from a phase I/II trial in Solid tumours and Glioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Glioma and solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top